Catalogo dei prodotti della ricerca

NATONI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 72
NA - Nord America 68
AS - Asia 34
AF - Africa 2
Totale 176
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 68
IT - Italia 37
DE - Germania 22
IN - India 19
SG - Singapore 13
IE - Irlanda 3
SE - Svezia 3
BY - Bielorussia 2
CN - Cina 2
EG - Egitto 2
FI - Finlandia 2
GB - Regno Unito 2
LV - Lettonia 1
Totale 176
Salva come PNG Salva come JPEG
Città #
Rome 22
Ashburn 18
Pune 17
Singapore 6
Milan 5
New York 4
Dublin 3
Keams Canyon 2
Lappeenranta 2
Minsk 2
West Jordan 2
Boardman 1
Chiswick 1
Delhi 1
Florence 1
Hounslow 1
Los Angeles 1
Miami 1
Phoenix 1
Reggio Emilia 1
Shimla 1
Xiamen 1
Totale 94
Salva come PNG Salva come JPEG
Nome #
Sialylation regulates migration in chronic lymphocytic leukemia 22
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY 9
Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma 8
Engineering CD38 low natural killer cells to transiently express CD16 (f158v) m-RNA enhances the cytotoxic potential of daratumumab against multiple myeloma with minimal NK cell fratricide 8
A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13) 7
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment 7
CD38(low) Natural Killer Cells Transiently Expressing CD16(F158V) m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide 7
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response 7
iCARE-2 fellowship 6
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models 6
Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells 6
Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study 6
Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma 6
Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP 6
Combination targeting of sialylation and the proteasome inhibits tumor growth and increases survival in a humanized mouse multiple myeloma model 6
E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271 6
Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells 6
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis 5
A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization 5
Chronic nitric oxide exposure induces prostate cell carcinogenesis, involving genetic instability and a pro-tumorigenic secretory phenotype 5
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP 5
TARGETING SIGLEC-7: A NOVEL IMMUNOTHERAPEUTIC APPROACH TO POTENTIATE THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA 5
PSGL-1 decorated with sialyl Lewisa/x promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement 5
Treatment of proliferative disorders with a death receptor agonist 5
Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor 5
Novel kinase inhibitors afuresertib and pim447 are active in a predictive myeloma in vivo model, and a crispr genome-wide screening approach identifies biomarkers determining susceptibility 4
Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment 4
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity 4
Low dose cyclophosphamide potentiates the anti-myeloma activity of daratumumab through augmentation of macrophage-induced ADCP 4
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis 4
Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor 3
Calicivirus translation initiation requires an interaction between VPg and eIF 4 E 3
Novel kinase inhibitors afuresertib and PIM447 are active alone and in combination with standard therapies, respectively, in a predictive MM in vivo model, and a CRISPR genome-wide screening approach identifies clinically-relevant biomarkers determining susceptibility to these therapeutic strategies 3
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study 3
Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo 3
The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia 3
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271 3
Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killar Cell-Mediated Cytotoxicity 3
PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL 3
Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model 3
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14) 2
Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model 2
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants 2
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model 2
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses 2
Targeting siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer cells against multiple myeloma 2
Targeting Selectins and Their Ligands in Cancer 2
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2 1
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma 1
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors 1
Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells 1
Targeting AML through DR4 with a novel variant of rhTRAIL 1
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide 1
NOXA contributes to the sensitivity of PERK-deficient cells to ER stress 1
Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation 1
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells 1
The mitochondrial pathway of apoptosis is triggered during feline calicivirus infection 1
Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment 1
Targeting the Pim kinases in multiple myeloma 1
Totale 245
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.497
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 66
selected - selezionate 0
volume - volumi 0
Totale 3.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023107 0 0 0 0 0 0 0 0 67 8 32 0
2023/2024138 8 20 6 13 16 41 12 1 4 17 0 0
Totale 245